Clinical Trial Update: Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 adjuvant trial evaluating PD-1 blockade for high-risk Stage II colorectal cancer with mismatch repair deficiency or MSI-H, currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer, Microsatellite Instability High | Phase 3 | Status: RECRUITING